AURA vs CSTL
AURA: Aura Biosciences is a clinical-stage biotech developing precision Viral-like Drug Conjugate (VDC) therapies designed to treat solid tumors while preserving organ function. CSTL: Castle Biosciences provides specialized molecular diagnostic tests to improve risk stratification and personalized treatment decisions for patients with skin cancers, Barrett's esophagus, and atopic dermatitis.
Side-by-side fundamentals
| Metric | AURA | CSTL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $7.01 | $24.81 | |
| Market cap as of 2026-07-23 | $725M | $749M | |
| PEG as of 2026-07-23 | n/a | -0.49 | |
| Net margin as of 2026-07-23 | n/a | -3.8% | |
| Gross margin as of 2026-07-23 | n/a | +77.9% | |
| Operating margin as of 2026-07-23 | n/a | -9.8% | |
| ROE as of 2026-07-23 | -78.1% | -2.8% | CSTL higher |
| ROA as of 2026-07-23 | -64.1% | -2.3% | CSTL higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.03 | AURA lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -2.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +35.9% | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 0.40 | 1.02 | |
| 1-year return as of 2026-07-22 close | +3.8% | +52.0% | CSTL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.